Remsima Stars In Orion Pharma’s First Half
Sales in Scandinavia of the biosimilar infliximab drove Orion’s specialty business in the first six months of 2016.
Sales in Scandinavia of the biosimilar infliximab drove Orion’s specialty business in the first six months of 2016.